-
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
•
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an active Vitamin D3 derivative, in China. The drug, approved in December 2020 for treating osteoporosis in postmenopausal women, will be promoted by Chugai Pharma China Co., Ltd and Roche’s local unit. Drug ProfileEdirol, first approved…
-
Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study
•
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144 has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of pruritus. The drug, a selective opioid agonist, was previously approved for pain relief in China. Drug ProfileRFUS-144 is being…
-
Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China
•
China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International Trade Co., Ltd to accelerate the commercialization of its anti-COVID-19 antibody cocktail, BRII-196 plus BRII-198 (amubarvimab/romlusevimab), in China. The collaboration will focus on warehousing, channel distribution, regional access, and other innovative aspects, though financial details…
-
Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China
•
Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at…
-
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
•
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership with Wuhan YZY Biopharma Co., Ltd, originally signed in September 2020. The deal granted Lummy exclusive priority sales rights to YZY Bio’s Y400, a bispecific antibody (BsAb) targeting VEGFA and ANG2, in Greater China. YZY…
-
HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China
•
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study for HMPL-A83, its monoclonal antibody (mAb) targeting CD47, in patients with advanced malignant tumors. The first patient was dosed on July 15, 2022. Study DetailsThe multi-center, open-label Phase I trial (NCT05429008) will evaluate the safety,…
-
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in Holland-based Xeltis AG, along with an exclusive license for the development, manufacturing, and commercialization of Xeltis’s endogenous tissue repair product aXess in Greater China. The deal, valued at €15 million ($15.2 million), grants Grand Pharma…
-
Fermion Secures Series B Financing to Advance AI-Driven Drug Development
•
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B financing round led by iFLYTEK Venture Capital, Zhengxuan Capital, Panda Capital, and Challenjers Venture Capital. The funds will advance its core drug pipelines, including a Phase I clinical study for FZ002, a chronic pain candidate,…
-
Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform
•
Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A financing round led by Qiming Venture Partners. The funds will support platform expansion, R&D, production, and market promotion. Company BackgroundFounded in 2012, Biotree conducts metabolomic and proteomic research on human, animal, plant, and microbial samples.…
-
Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials
•
China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with Shenzhen Antaiwei Biopharmaceutical Co., Ltd, has received approval from the National Medical Products Administration (NMPA) to proceed with clinical trials. Drug ProfileSHEN26 is a novel coronavirus polymerase (RdRp) inhibitor that blocks viral nucleic acid synthesis.…
-
WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform
•
China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation Zone to establish a dual-platform system combining an Internet health platform and an Internet traditional Chinese medicine (TCM) exchange platform. The collaboration builds on a previous provincial Internet health service platform focused on TCM digital…
-
ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation to its bispecific antibody (BsAb)-receptor recombinant protein IMM2902, targeting human CD47 and HER2. The product is the only CD47/HER2 BsAb to enter clinical trials globally. Drug ProfileIMM2902 inhibits tumor cell growth by…
-
VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed
•
China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products worth over RMB4.4 billion ($651 million). The results, released by VBP authorities, show Shijiazhuang No. 4 Pharmaceutical Co. Ltd as the top contract winner, while six foreign firms secured deals totaling RMB76.7 million (1.7% of…
-
Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000
•
Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up to €100,000 ($101,000) to startups in healthcare, life science, electronics, and smart manufacturing. The initiative aims to identify early-stage companies and support proof-of-concept studies, pilot projects, and partnerships with Merck. Program DetailsUptune is open to…
-
Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach
•
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell lung cancer (NSCLC), marking the PD-L1 inhibitor’s second approved indication in the country. The therapy, developed by CStone Pharmaceuticals (HKG: 2616) under a license from Ligand Pharmaceuticals (NASDAQ: LGND), is now the only immunotherapy approved…
-
Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of its generic drug and “non-core” conventional medicine businesses. The move follows a strategic review aimed at refocusing resources on higher-growth sectors. Strategic RationaleThe board intends to offload products not aligned with performance expectations or long-term…
-
Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment
•
China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for lurbinectedin (LY01017), an RNA polymerase II inhibitor, to treat metastatic small-cell lung cancer (SCLC) in patients with disease progression after chemotherapy. The drug will be available through Hainan’s Boao Lecheng International Medical Tourism Pilot Zone,…
-
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
•
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first time at Guangzhou United Family Hospital, marking its launch in China through the Greater Bay Area (GBA) early access scheme. The University of Hong Kong-Shenzhen Hospital and Chan Xinghai Hospital have also been approved to…
-
CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC
•
CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval in Hong Kong for treating adults with RET fusion-positive metastatic non-small cell lung cancer (NSCLC). The drug, licensed from US-based Blueprint Medicines in June 2018, was approved based on data from the global Phase I/II…
-
NMPA Approves RocketHeart’s LV Assist System and Our United Group’s Radiation Therapy Device
•
The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s implantable left ventricular assist system and Our United Group’s gamma beam stereotactic radiation therapy system. Both products feature proprietary technologies and mark firsts in China’s medical device landscape. RocketHeart’s LV Assist SystemRocketHeart’s device provides mechanical…
